Key points are not available for this paper at this time.
Abstract To explore the efficacy and safety of oral isavuconazole in the treatment of invasive pulmonary aspergillosis (IPA) through a retrospective study. The clinical and laboratory data of patients admitted to the Respiratory Intensive Care Unit (RICU) of Huaian No.1 People’s Hospital from 1 March 2023 to 29 February 2024, clinically diagnosed with IPA, and treated with oral isavuconazole were retrospectively analyzed. A total of 31 patients were involved, including 10 dead and 21 survivors at 42 days. The average hospitalization time was 21.81 ± 8.03 days. The average usage time of isavuconazole was 25.10 ± 12.87 days, while the survival group was greater than the death group (28.62 ± 12.56 days vs 17.70 ± 10.56 days) (P = 0.025). The average time frame between hospitalization and isavuconazole administration was 9.97 ± 7.08 days. The survival group was significantly shorter than the death group (7.86 ± 4.51 days vs 14.4 ± 9.47 days) (P = 0.013). Among the surviving patients, the average hospitalization time for early use was shorter than that for late use (16.33 ± 2.65 days vs 25.83 ± 5.87 days) (P 0.05), and no patient was required to discontinue isavuconzole use due to an adverse event. Early oral administration of isavuconazole may reduce mortality rates and hospitalization time, with fewer adverse reactions and a high level of safety.
Gu et al. (Tue,) studied this question.